Shareholders Investigation of Immunomedics

Immunomedics, Inc. (IMMU) Accused of Data Integrity Breach

According to the filed complaint against the company for alleged violations of the Securities Exchange Act of 1934 between August 23, 2018, and December 20, 2018, on December 17, 2018, FDAnews.com published an article, stating that “he FDA cited Immunomedics, Inc. (IMMU) for a host of violations – including its handling of a data integrity breach – observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.” The breach purportedly included “manipulated bioburden samples, misrepresentations of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.” On December 20, 2018, Favus Institutional Research issued its own report discussing the data integrity breach. On this news, Immunomedics’ stock fell 20% to close at $14.17 on December 20, 2018. The stock currently trades at $13.24.

If you are a former employee of Immunomedics, Inc. (IMMU) and own stock, please contact us for more information about your rights and potential remedies.

Send us a message for more information.

Protect your investments.

Sign up for free investment monitoring.

Stock Watch members receive free investment monitoring and notifications.  

Leave your details to get started

"*" indicates required fields

Name*
Ticker + Amount
This field is for validation purposes and should be left unchanged.

Skip to content